Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib vs Vinflunine or Docetaxel or Pembrolizumab in Advanced Urothelial Cancer with FGFR Aberrations
2023-510296-56-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised trial of erdafitinib in transitional cell carcinoma (TCC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall survival. Started Apr 2024; status: completed.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-510296-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510296-56-00.